Biotechnology Kluska and Duncan, along with Louise Vetter, President & CEO of Huntington’s Disease Society of America, discuss current treatment paradigm and the unmet need in the Huntington Disease patient and caregiver community on an Analyst/Industry conference call to be held on March 25 at 2 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target lowered to $7 from $10 at Mizuho
- uniQure price target lowered to $25 from $30 at H.C. Wainwright
- Snowflake downgraded and upgraded: Wall Street’s top analyst calls
- Goldman downgrades uniQure on uncertain path in Huntington’s
- uniQure downgraded to Neutral from Buy at Goldman Sachs
